Abstract
Since its inception in 1995, the Biopharmaceutics Classification System (BCS) has become an increasingly important tool for regulation of drug product development worldwide. The regulations with respect to biowaivers for immediate-release solid oral dosage forms in the United States, the EU, and from the World Health Organization are summarized and compared in this article. On this basis, technical requirements for BCS-based biowaiver in China are proposed, and biowaiver eligibility of immediate-release oral products in the China Pharmacopoeia 2005, and the top 200 best sale list in 2008 are evaluated, which shows a similar trend to those found in the top 200 lists from the United States and Great Britain.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
